Skip to main content

Table 2.

Results of treatment

Response
 CR (incl. CRu) 17/30 (57%)
 PR  5/30 (17%)
Disease status
 Relapsed CR 16/26 (62%)
 Primary refractory  1/4  (25%)
Survival (median follow up; 19 months)
 Overall survival (2 years) 45.2%
 Progression‐free survival (2 years) 37.2%